Directorate change

Directorate change

December 4, 2015

December 4, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following appointments to committees of the Board with effect from December 3, 2015:


Board committee

Steven Gillis2

Audit, Compliance & Risk Committee

David Ginsburg

Nomination Committee

Sara Mathew

Remuneration Committee

1. Each director will serve as a member of the respective Board committee.
2. Dr. Gillis has served as an interim member of the Audit, Compliance & Risk Committee since December 3, 2014.

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations



Matthew Osborne

[email protected]

+1 781 482 9502

Sarah Elton-Farr

[email protected]

+44 1256 894157


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.